Brokerages expect that Shire PLC (NASDAQ:SHPG) will report earnings of $3.66 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Shire’s earnings, with the highest EPS estimate coming in at $3.80 and the lowest estimate coming in at $3.58. Shire posted earnings per share of $3.73 in the same quarter last year, which suggests a negative year-over-year growth rate of 1.9%. The company is scheduled to report its next earnings results on Thursday, August 2nd.
According to Zacks, analysts expect that Shire will report full year earnings of $15.27 per share for the current year, with EPS estimates ranging from $15.05 to $15.50. For the next year, analysts expect that the firm will report earnings of $16.35 per share, with EPS estimates ranging from $15.08 to $17.50. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Shire.
Shire (NASDAQ:SHPG) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.58 by $0.28. Shire had a net margin of 28.96% and a return on equity of 13.60%. The company had revenue of $3.77 billion for the quarter. During the same quarter in the previous year, the company posted $3.63 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year.
Several research analysts have weighed in on SHPG shares. BidaskClub upgraded shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, March 30th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Monday, April 9th. Kepler Capital Markets restated a “buy” rating on shares of Shire in a research report on Friday, May 11th. Bank of America restated a “buy” rating on shares of Shire in a research report on Wednesday, March 28th. Finally, BTIG Research restated a “buy” rating and set a $195.00 target price on shares of Shire in a research report on Sunday, April 29th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $201.64.
Several hedge funds and other institutional investors have recently made changes to their positions in SHPG. SeaCrest Wealth Management LLC purchased a new stake in shares of Shire in the fourth quarter valued at about $107,000. Sei Investments Co. lifted its holdings in shares of Shire by 22.0% in the fourth quarter. Sei Investments Co. now owns 36,017 shares of the biopharmaceutical company’s stock valued at $5,588,000 after purchasing an additional 6,489 shares in the last quarter. Greenleaf Trust lifted its holdings in shares of Shire by 1,282.2% in the fourth quarter. Greenleaf Trust now owns 2,253 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 2,090 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Shire by 9.3% in the fourth quarter. First Trust Advisors LP now owns 305,452 shares of the biopharmaceutical company’s stock valued at $47,382,000 after purchasing an additional 26,012 shares in the last quarter. Finally, Independence Bank of Kentucky purchased a new stake in shares of Shire in the fourth quarter valued at about $256,000. 17.90% of the stock is currently owned by institutional investors.
Shire traded down $0.55, hitting $161.85, on Friday, according to MarketBeat Ratings. 719,176 shares of the company were exchanged, compared to its average volume of 860,216. The company has a current ratio of 1.14, a quick ratio of 0.66 and a debt-to-equity ratio of 0.45. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $177.51. The firm has a market capitalization of $49.36 billion, a P/E ratio of 10.68, a PEG ratio of 1.35 and a beta of 1.29.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.